Table 1

Diagnoses, disease duration, disease damage and disease activity scores in patients with vasculitis

Diagnosisn (%)Median disease duration in months (range)VDI median score (range)CDA median score (range)BVAS v3 median score (range)
Wegener's granulomatosis (with renal involvement)104 (36.8)36 (0–396)2 (0–12)4 (0–26)1 (0–36)
Wegener's granulomatosis (without renal involvement)61 (21.6)60 (1–300)3 (0–8)4 (0–21)1 (0–39)
Microscopic polyangiitis31 (11.0)18.5 (0–252)2 (0–7)3 (0–12)0 (0–25)
Churg–Strauss syndrome24 (8.5)38 (2–240)3 (0–12)3 (0–15)2 (0–22)
Other vasculitis*17 (6.0)20.5 (0–228)1 (0–9)2 (0–16)2 (0–17)
Henoch–Schönlein purpura11 (3.9)39 (2–360)1 (0–5)1 (0–11)2 (0–15)
Mixed essential cryoglobulinaemia11 (3.9)49 (3–420)2 (0–6)4.5 (0–10)6.5 (0–26)
Behçet's disease9 (3.2)60 (7–480)3 (0–7)5 (1–8)4 (0–18)
Takayasu's arteritis7 (2.5)109 (36–264)3 (0–4)4 (0–7)0 (0–4)
Isolated skin vasculitis4 (1.4)20.5 (4–78)0 (0–4)0.5 (0–9)3.5 (2–5)
Polyarteritis nodosa (not HBV associated)2 (0.7)160 (114–206)0.5 (0–1)1 (0–2)0.5 (0–1)
Systemic rheumatoid vasculitis2 (0.7)40 (32–48)1.5 (1–2)2 (2–2)1 (1–1)
  • * Other vasculitis comprised of: ANCA positive vasculitis not fitting any specific diagnosis (four patients); unspecified small vessel vasculitis (three patients); CNS vasculitis (three patients); not further specified (two patients); SLE vasculitis (one patient); giant cell arteritis (one patient); hypocomplementemic urticarial vasculitis (one patient), drug-induced vasculitis (one patient), Goodpasture's syndrome (one patient).

  • ANCA, anti-neutrophil cytoplasmic antibody; BVAS v3, Birmingham Vasculitis Activity Score version 3; CDA, Combined Damage Assessment Index; CNS, central nervous system; HBV, hepatitis B virus; SLE, systemic lupus erythematosus; VDI, Vasculitis Damage Index.